Research Topics
Genomes and GenesSpecies | Syma IqbalSummaryAffiliation: University of Southern California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patientsMizutomo Azuma
University of Southern California Norris Comprehensive Cancer Center, Division of Medical Oncology, The Sharon Carpenter Laboratory, Keck School of Medicine, 1441 Eastlake Avenue, Suite 3456, Los Angeles, CA 90033, USA
Pharmacogenomics 8:1705-13. 2007..e., VEGFA, VEGFR1-3, and neuropilin [NRP]1) are upregulated in metastatic colorectal cancer (mCRC) patients with high serum lactate dehydrogenase (LDH)...
Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancerS Iqbal
Division of Medical Oncology, University of Southern California, Los Angeles, 90033, USA
Ann Oncol 22:2610-5. 2011....- Molecular predictors of treatment and outcome in colorectal cancerSyma Iqbal
Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Suite 3450, Los Angeles, CA 90033, USA
Curr Gastroenterol Rep 5:399-405. 2003..We discuss the ways in which determination of gene expression levels can enhance the treatment of colorectal cancer through prediction of patient response and tailoring of chemotherapy to the characteristics of an individual tumor... - A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202Syma Iqbal
Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Ave, Rm 3457, Los Angeles, CA 90033, USA
Cancer Chemother Pharmacol 68:1595-602. 2011..Patients with gallbladder cancer or cholangiocarcinoma were treated with the combination of gemcitabine 1,000 mg/m(2) IV over 100 min on days 1 and 8 and capecitabine 650 mg/m(2) BID PO on days 1-14, administered every 21 days... - Tailored chemotherapy for colorectal cancer: a new approach to therapySyma Iqbal
University of Southern California Norris Comprehensive Cancer Center, Division of Medical Oncology, Los Angeles, California 90033, USA
Cancer Invest 22:762-73. 2004..The integration of these prognostic and predictive markers would allow individualized treatment for patients, maximizing therapeutic effect and minimizing exposure to toxicity... - Molecular determinants of irinotecan efficacyDaniel Vallbohmer
Divison of Medical Oncology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, 90033, USA
Int J Cancer 119:2435-42. 2006..This small retrospective study suggests that gene expression levels of EGFR, ERCC1 and GST-P1 may be useful in predicting the clinical outcome of patients with metastatic CRC treated with first-line CPT-11 based chemotherapy... 
Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancerOliver A Press
Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
Cancer Res 68:3037-42. 2008..This study supports the role of functional EGFR polymorphisms as independent prognostic markers in metastatic colon cancer. As a prognostic factor, these variants had opposite prognostic implications based on gender...- Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with CetuximabWu Zhang
Division of Medical Oncology, Department of Preventive Medicine, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
Pharmacogenet Genomics 16:475-83. 2006..004, log-rank test). The findings of this pilot study suggest that the cyclin D1 A870G and the EGF A61G polymorphisms may be useful molecular markers for predicting clinical outcome in CRC patients treated with single-agent Cetuximab... - ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecanKatrin E Rhodes
Divison of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
Drug Metab Lett 1:23-30. 2007..The combination of at least one SLCO1B1 521 T allele, one ABCB1 1236 C allele and one UGT1A1*28 variant 7 repeat demonstrated a statistically significant association with Grade 3/4 toxicities in metastatic colorectal cancer patients... - Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatinMichael A Gordon
Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
Pharmacogenomics 12:27-39. 2011..There is increasing evidence to suggest that gender-specific differences may contribute to poor clinical outcome. We tested the hypothesis that genomic profiling of metastatic colorectal cancer is dependent on gender... - FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximabWu Zhang
Division of Medical Oncology, Department of Pathology, University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
J Clin Oncol 25:3712-8. 2007..We tested the hypothesis of whether these two polymorphisms are associated with clinical outcome in metastatic CRC patients treated with single-agent cetuximab... - Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancerWu Zhang
Division of Medical Oncology, Department of Preventive Medicine, University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
J Clin Oncol 25:3726-31. 2007..We tested the hypothesis of whether these two polymorphisms are associated with sex-specific clinical outcome in metastatic colon cancer patients treated with FU-based chemotherapy... - Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiationMichael A Gordon
University of Southern California/Norris Comprehensive Cancer Center, Division of Medical Oncology, Keck School of Medicine, 1441 Eastlake Avenue, Suite 3456, Los Angeles, CA 90033, USA
Pharmacogenomics 7:67-88. 2006..A larger prospective study is needed to validate these preliminary data using germline polymorphisms on tumor recurrences in rectal cancer patients treated with chemoradiation... - Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumorsSyma Iqbal
Department of Medical Oncology, University of Southern California Norris Cancer Center, Los Angeles, CA 90033, USA
Am J Clin Oncol 34:27-31. 2011..The primary objective of this study was to determine the maximum tolerated dose (MTD) of pegylated liposomal doxorubicin (PLD) and docetaxel (T) administered in 4 week cycles in patients with advanced solid tumors... - A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapyPeter M Wilson
Department of Pathology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
Cancer Chemother Pharmacol 65:979-88. 2010..We conducted a phase I/II clinical trial to determine the safety and feasibility of combining vorinostat with 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer (mCRC) and elevated intratumoral thymidylate synthase (TS)... - Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinomaDeirdre J Cohen
Division of Medical Oncology, New York University Cancer Center, NYU Medical Center, New York, NY, USA
Ann Surg Oncol 19:478-85. 2012..However, locoregional recurrences remain high. Accordingly, we instituted this pilot/feasibility study, including intraperitoneal 5-fluoro-2'-deoxyuridine (IP FUDR) as part of the treatment... - Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancerGeorg Lurje
Division of Medical Oncology, Department of Preventive Medicine, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, California 90033, USA
Pharmacogenet Genomics 18:161-8. 2008.... - Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancerMizutomo Azuma
Division of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
Clin Colorectal Cancer 6:214-8. 2006..6%) with a range of 0.38-2.83. CONCLUSION: Our results demonstrate that the expression of EGFRvIII is rare, but most colon cancer demonstrates EGFR gene expression. We conclude that EGFRvIII does not play an important role in mCRC... - Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosisAgustin A Garcia
University of Southern California Keck School of Medicine, Kenneth Norris Jr Comprehensive Cancer Center, Los Angeles, CA, USA
Invest New Drugs 24:79-83. 2006..The objective of this phase I study was to determine the maximal tolerated dose (MTD) of the combination of weekly docetaxel and exisulind in patients with advanced solid tumors... - Capecitabine: the new generation of fluoropyrimidines in colorectal cancerSyma Iqbal
University of Southern California, Kenneth Norris Comprehensive Cancer Center, Division of Medical Oncology, 1441 Eastlake Avenue, Suite 3457, Los Angeles, CA 90033, USA
Expert Rev Anticancer Ther 4:947-55. 2004..Ongoing clinical trials are evaluating the efficacy of capecitabine in combination with oxaliplatin and irinotecan as more convenient substitutes for infusional 5-FU in the 5-FU/leucovorin/oxaliplatin and 5-FU/irinotecan regimens... - Molecular determinants of cetuximab efficacyDaniel Vallbohmer
Division of Medical Oncology, Department of Preventive Medicine, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
J Clin Oncol 23:3536-44. 2005.... - Angiogenesis inhibitors in the treatment of colorectal cancerSyma Iqbal
Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
Semin Oncol 31:10-6. 2004..Other potential targets of angiogenesis, such as the VEGF receptor and multi-targeted agents, are undergoing evaluation in clinical trials... - Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly scheduleAgustin A Garcia
Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
Cancer Chemother Pharmacol 56:75-82. 2005..CONCLUSIONS: The combination of weekly docetaxel and irinotecan is a well tolerated regimen and should be explored in phase II trials. This schedule maintains dose intensity and has limited myelosuppression... - Integration of novel agents in the treatment of colorectal cancerSyma Iqbal
Kenneth Norris Comprehensive Cancer Center, Division of Medical Oncology, University of Southern California/Keck School of Medicine, 1441 Eastlake Avenue, Ste 3457, Los Angeles, CA 90033, USA
Cancer Chemother Pharmacol 54:S32-9. 2004..The goal in the future will be to predict which specific chemotherapy and targeted agent combination will most likely benefit individual patients... - Targeted therapy and pharmacogenomic programsSyma Iqbal
Division of Oncology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA
Cancer 97:2076-82. 2003..The next step is to develop clinical trials that will assess prospectively the benefits of profiling a patient's particular tumor, which should translate into an improvement in response and toxicity... - A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levelsMichael V Mandola
Department of Molecular Biology, The University of Medicine and Dentistry of New Jersey, School of Osteopathic Medicine, Stratford, New Jersey 08084, USA
Pharmacogenetics 14:319-27. 2004..A 6 bp deletion polymorphism in the thymidylate synthase (TS) gene was investigated in order to determine its function...